Illinois Municipal Retirement Fund Purchases 14,230 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Illinois Municipal Retirement Fund lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.2% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 289,268 shares of the biopharmaceutical company's stock after buying an additional 14,230 shares during the period. Gilead Sciences makes up 0.5% of Illinois Municipal Retirement Fund's holdings, making the stock its 28th largest position. Illinois Municipal Retirement Fund's holdings in Gilead Sciences were worth $32,412,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Diversified Trust Co boosted its position in shares of Gilead Sciences by 1.1% during the 1st quarter. Diversified Trust Co now owns 34,838 shares of the biopharmaceutical company's stock valued at $3,904,000 after purchasing an additional 383 shares in the last quarter. Alta Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 3.4% in the 1st quarter. Alta Wealth Advisors LLC now owns 12,438 shares of the biopharmaceutical company's stock worth $1,394,000 after purchasing an additional 411 shares in the last quarter. Stone Summit Wealth LLC lifted its stake in Gilead Sciences by 6.0% during the first quarter. Stone Summit Wealth LLC now owns 32,348 shares of the biopharmaceutical company's stock valued at $3,625,000 after purchasing an additional 1,845 shares during the last quarter. Nadler Financial Group Inc. bought a new stake in Gilead Sciences during the first quarter worth approximately $225,000. Finally, PDS Planning Inc grew its position in Gilead Sciences by 11.3% in the first quarter. PDS Planning Inc now owns 5,198 shares of the biopharmaceutical company's stock worth $582,000 after buying an additional 528 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on GILD shares. Bank of America raised their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Wells Fargo & Company upped their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Oppenheimer reduced their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Finally, Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Price Performance

Gilead Sciences stock traded up $3.05 during trading hours on Friday, hitting $110.67. 19,541,254 shares of the stock were exchanged, compared to its average volume of 7,687,732. Gilead Sciences, Inc. has a 12 month low of $66.01 and a 12 month high of $119.96. The business's 50-day moving average is $106.27 and its two-hundred day moving average is $103.15. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The stock has a market capitalization of $137.67 billion, a P/E ratio of 23.30, a P/E/G ratio of 0.69 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.32) EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.86%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $330,510.00. Following the transaction, the insider now owns 120,168 shares in the company, valued at $13,238,908.56. The trade was a 2.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. This trade represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,500 shares of company stock worth $5,236,245. Insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.